Active, not recruitingPhase 3NCT06118255
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Studying Dravet syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UCB BIOSCIENCES, Inc.
- Principal Investigator
- UCB Cares001 844 599 2273
- Intervention
- fenfluramine(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2024 – 2026
Study locations (12)
- Ep0213 105, Memphis, Tennessee, United States
- Ep0213 107, Dallas, Texas, United States
- Ep0213 103, Seattle, Washington, United States
- Ep0213 502, Brussels, Belgium
- Ep0213 501, Edegem, Belgium
- Ep0213 303, Bielefeld, Germany
- Ep0213 202, Florence, Italy
- Ep0213 203, Genova, Italy
- Ep0213 201, Roma, Italy
- Ep0213 204, Roma, Italy
- Ep0213 403, Glasgow, United Kingdom
- Ep0213 401, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06118255 on ClinicalTrials.govOther trials for Dravet syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07251673Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene MutationAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06872125A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeStoke Therapeutics, Inc
- RECRUITINGPHASE4NCT06598449Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of AgeUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT06660394A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Longboard Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT05419492A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromeEncoded Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06283212A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet SyndromeEncoded Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06112275A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)Encoded Therapeutics
- ENROLLING BY INVITATIONNANCT06371794EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype HeterogeneityFondazione Policlinico Universitario Agostino Gemelli IRCCS